HIV/AIDS
Tenofovir disoproxil fumarate with emtricitabine
Brand: Truvada®
PBAC's latest decision on Tenofovir disoproxil fumarate with emtricitabine: Recommended with restriction (2005). Considered for Treatment of HIV infection in patients with: (a) CD4 cell counts of less than 500 per cubic millimetre; or (b) viral load of greater than 10,000 copies per mL.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
2005 → 2005
Eligible population HIV infected adults over the age of 18 years
Therapy area HIV/AIDS Line of therapy Not applicable Evidence base RCT, Single-arm Key trials randomised open-label cross-over trial, randomised, cross-over trial, supporting randomised trial Comparator concomitant tenofovir disoproxil fumarate and emtricitabine Economic model Cost-minimisation ICER note Cost-minimisation analysis undertaken; no ICER calculated by design Open on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.